Kamada EBITDA Margin 2012-2021 | KMDA

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Kamada (KMDA) over the last 10 years. The current EBITDA margin for Kamada as of September 30, 2021 is .
Kamada EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2021-09-30 $0.10B $0.01B 9.62%
2021-06-30 $0.12B $0.02B 16.38%
2021-03-31 $0.13B $0.02B 17.60%
2020-12-31 $0.13B $0.02B 18.05%
2020-09-30 $0.13B $0.03B 20.30%
2020-06-30 $0.13B $0.03B 19.08%
2020-03-31 $0.13B $0.03B 21.05%
2019-12-31 $0.13B $0.03B 22.05%
2019-09-30 $0.14B $0.04B 25.87%
2019-06-30 $0.13B $0.03B 22.40%
2019-03-31 $0.12B $0.03B 20.97%
2018-12-31 $0.11B $0.02B 19.30%
2018-09-30 $0.10B $0.01B 12.75%
2018-06-30 $0.11B $0.02B 14.55%
2018-03-31 $0.11B $0.02B 14.68%
2017-12-31 $0.10B $0.01B 10.58%
2017-09-30 $0.09B $0.00B 3.26%
2017-06-30 $0.09B $0.00B 2.27%
2017-03-31 $0.07B $-0.00B -5.41%
2016-12-31 $0.08B $-0.00B -2.60%
2016-09-30 $0.08B $0.00B 1.27%
2016-06-30 $0.08B $-0.00B -2.63%
2016-03-31 $0.08B $-0.00B -5.26%
2015-12-31 $0.07B $-0.01B -11.43%
2015-09-30 $0.07B $-0.01B -10.00%
2015-06-30 $0.07B $-0.01B -8.45%
2015-03-31 $0.07B $-0.01B -16.18%
2014-12-31 $0.07B $-0.01B -11.11%
2014-09-30 $0.07B $-0.01B -11.43%
2014-06-30 $0.07B $-0.00B -5.71%
2014-03-31 $0.07B $0.01B 7.14%
2013-12-31 $0.07B $0.01B 10.00%
2013-09-30 $0.07B $0.03B 38.24%
2013-06-30 $0.07B $0.03B 36.23%
2013-03-31 $0.07B $0.04B 55.22%
2012-12-31 $0.07B $0.06B 77.03%
2012-09-30 $0.10B $0.08B 82.65%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.281B $0.133B
Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09